Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY: BHVN )

29.41 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 104
Open 29.41
Bid (Size) 27.02 (8)
Ask (Size) 34.20 (1)
Prev. Close 29.41
Today's Range 29.41 - 29.41
52wk Range 26.80 - 60.83
Shares Outstanding 65,401,228
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced. 
Via Investor's Business Daily
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile. 
Via Benzinga

Performance

YTD
-21.11%
-21.11%
1 Month
-23.11%
-23.11%
3 Month
-31.27%
-31.27%
6 Month
-17.67%
-17.67%
1 Year
-49.80%
-49.80%

More News

Read More
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Via Benzinga
Why Biohaven Stock Triumphed on Tuesday
Via The Motley Fool
What's Going On With Merus Stock Monday?
Via Benzinga
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
Via Investor's Business Daily
Exposures Product Safety
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
Via Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Via Benzinga
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Via Benzinga
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Via MarketBeat
Dow Gains Over 50 Points; Elevai Labs Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Crude Oil Down Over 1%; US Manufacturing PMI Falls In September
Via Benzinga
Exposures Fossil Fuels
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise
Via Benzinga
Exposures Product Safety
Biohaven, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
Via Investor's Business Daily
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.